Yeqiang Shi, Hui Yao, Peng Zhang, Jun Yang, Lei Gao
{"title":"概念性玻璃体内注射治疗病理性近视继发脉络膜新生血管的预后因素。","authors":"Yeqiang Shi, Hui Yao, Peng Zhang, Jun Yang, Lei Gao","doi":"10.1177/11206721251351496","DOIUrl":null,"url":null,"abstract":"<p><p>PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, <i>P</i> = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, <i>P</i> = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, <i>P</i> = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, <i>P</i> = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251351496"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia.\",\"authors\":\"Yeqiang Shi, Hui Yao, Peng Zhang, Jun Yang, Lei Gao\",\"doi\":\"10.1177/11206721251351496\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, <i>P</i> = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, <i>P</i> = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, <i>P</i> = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, <i>P</i> = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.</p>\",\"PeriodicalId\":12000,\"journal\":{\"name\":\"European Journal of Ophthalmology\",\"volume\":\" \",\"pages\":\"11206721251351496\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/11206721251351496\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251351496","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的病理性近视继发脉络膜新生血管是导致病理性近视患者视力下降的重要因素。Conbercept是一种抗vegf药物,目前是PM-CNV的主要治疗方法。本研究利用光学相干断层血管造影(OCTA)数据探讨影响PM-CNV患者视觉预后的因素。方法回顾性分析2019年1月至2022年12月济南市第二人民医院眼科诊断的PM-CNV患者资料。所有患者在1 + pro re nata (PRN)方案后接受玻璃体内注射0.05 ml Conbercept (0.5 mg)。根据治疗后12个月的视力分为改善组(最佳矫正视力[BCVA]改善bbb1线)和非改善组(BCVA改善≤1线或视力降低)。采用logistic回归分析治疗后BCVA的影响因素。结果治疗12个月后,改善组77例,未改善组23例。多变量logistic回归分析显示,年龄(优势比(OR) = 1.303, 95%可信区间(CI): 1.059 ~ 1.603, P = 0.012)、基线BCVA (OR = 15.939, 95% CI: 2.490 ~ 102.013, P = 0.003)、中央窝下CNV (OR = 0.055, 95% CI: 0.010 ~ 0.312, P = 0.001)、组织良好的CNV (OR = 0.049, 95% CI: 0.009 ~ 0.276, P = 0.001)与PM-CNV患者玻璃体内注射conberept的疗效独立相关。结论妊娠期PM-CNV患者玻璃体内注射后BCVA恢复不良可能与年龄、基线BCVA、CNV的位置和形态有关。
Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia.
PurposeChoroidal neovascularization secondary to pathologic myopia (PM-CNV) is an important main factor leading to decreased vision in patients with pathologic myopia. Conbercept, an anti-VEGF drug, is currently the primary treatment for PM-CNV. This study used optical coherence tomography angiography (OCTA) data to investigate the factors influencing the visual prognosis of patients with PM-CNV.MethodsData from patients with PM-CNV diagnosed in the Department of Ophthalmology of The Second People's Hospital of Jinan City from January 2019 to December 2022 were retrospectively analyzed. All patients received intravitreal injections of 0.05 ml Conbercept (0.5 mg) following a 1 + pro re nata (PRN) regimen. Patients were divided into two groups based on visual acuity at 12 months after treatment: improved (best-corrected visual acuity [BCVA] improvement > 1 line) and non-improved (BCVA improvement ≤ 1 line or reduced visual acuity). The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR) = 1.303, 95% confidence interval (CI): 1.059-1.603, P = 0.012), baseline BCVA (OR = 15.939, 95% CI: 2.490-102.013, P = 0.003), subfoveal CNV (OR = 0.055, 95% CI: 0.010-0.312, P = 0.001), and well-organized CNV (OR = 0.049, 95% CI: 0.009-0.276, P = 0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.
期刊介绍:
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.